Table 2.

siRNA-based therapeutics for lung cancer treatment in in vivo studies.

Target Gene	Administration	Type of siRNA Delivery	References
RPN2	Intratracheal	Naked nucleic acids	[20]
C7orf24	Intratumoral	Naked nucleic acids	[27]
Mcl1	Intratracheal	Ethylphosphocholine-based lipoplexes	[28]
CD31	Intravenous	AtuFECT01 lipoplexes	[29]
IGF-1R	Intravenous	Magnetic lipoplexes	[56]
Survivin	Intravenous	Liposomes	[31]
	Intravenous	Polyethylenimine (PEI)	[32,33]
MRP1	Inhalation	Liposomes	[34]
Luciferase	Inhalation	Chitosan	[36]
	Intravenous	Lipid/Calcium/Phosphate (LCP)	[37]
Bcl-2	Intravenous	Cationic bovine serum albumin	[38]
Akt1	Inhalation	Glycerol propoxylate triacrylate-spermine	[39,40]
NPT2b	Inhalation	Glycerol propoxylate triacrylate-spermine	[41]
MDM2	Intravenous	Poly(methacryloyloxy ethyl phosphorylcholine)-block-poly(diisopropanolamine ethyl methacrylate) (PDMA-b-PDPA)	[42]
STAT3	Intraperitoneal	PEI and poly-l-lactic-co-glycolic acid (PLGA)	[44]
MDM2, c-myc, VEGF	Intravenous	LCP	[43]
VEGF	Intravenous	LCP	[46]
c-Myc	Intratracheal	Arginine-glycine-aspartic acid (RGD) gold nanoparticles	[45]
MRP1 and Bcl-2	Inhalation	Lutein hormone releasing hormone (LHRH)-modified mesoporous silica nanoparticles (MSN)	[35]